TXMD - Therapeutics MD GAAP EPS of $12.39 revenue of $28.6M
- Therapeutics MD press release ( NASDAQ: TXMD ): Q2 GAAP EPS of $12.39.
- Revenue of $28.6M (+24.3% Y/Y).
- As of June 30, 2022, the Company’s cash on hand totaled $26.3 million, compared with $65.1 million as of December 31, 2021.
For further details see:
Therapeutics MD GAAP EPS of $12.39, revenue of $28.6M